The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Diagnosing, Treating IgG4-Related Disease

Diagnosing, Treating IgG4-Related Disease

September 15, 2015 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Lightspring/shutterstock.com

Image Credit: Lightspring/shutterstock.com

In diagnosing and treating a disease that is rapidly gaining recognition worldwide since it was first recognized in Japan in 2003, 42 experts from 10 different countries recently collaborated to discuss and review the current experience and data on IgG4-related disease.

You Might Also Like
  • International Consensus Statement on the Management & Treatment of IgG4-Related Disease
  • Resarch Into IgG4-Related Diseases Expands Knowledge Base, Leads to Effective Treatments
  • Draft Classification Criteria for IgG4-Related Disease Introduced
Explore This Issue
September 2015
Also By This Author
  • Mortality Rates Improve for Patients with Rheumatoid Arthritis

The result is the “International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease,” published in July 2015 in Arthritis & Rheumatology.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

A Systemic Disorder

Defined as a fibroinflammatory condition mediated by the immune system that can affect multiple organs and lead to tumefactive, tissue-destruction lesions and organ failure, IgG4-related disease is now recognized as a systemic disorder that links many individual organ conditions once thought not to be related.1

Diagnosis is complicated by the many conditions that can mimic the disease. The disease is often mistaken for a malignancy, an infection or other immune-mediated conditions, such as Sjögren’s syndrome, giant cell arteritis or granulomatosis with polyangiitis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“IgG4-related disease is an emerging systemic condition linking many disorders once regarded as isolated, single-organ conditions that were managed by different subspecialties,” says Arezou Khosroshahi, MD, assistant professor of medicine, Rheumatology Division, Emory University School of Medicine, Atlanta, and lead author of the study. “Most patients with IgG4-related disease undergo multiple invasive procedures for suspected malignancy before the diagnosis is considered, which delays their diagnosis and on-time treatment.”

According to Dr. Khosroshahi, the disease has only been recognized in the U.S. in the past decade and published evidence on the disease is still quite thin, with no prospective, randomized trials yet available.

Given the rapid recognition of the disease within the past decade, however, experts felt some guidance was needed to help clinicians diagnose and manage a complicated disease that can affect multiple organs, most commonly the pancreas, biliary tract, major salivary glands, lacrimal glands, retroperitoneum and lymph nodes. Indeed, because of the widespread anatomical areas in which the disease can present, experts representing eight specialties (i.e., gastroenterology, rheumatology, ophthalmology, pulmonary-critical care, hematology/oncology, internal medicine, nephrology and endocrinology) were among the experts included in the development of the consensus statement.

Table 1: 7 Key Consensus Statements

(Click for larger image)
Table 1: 7 Key Consensus Statements
Adapted and compiled from References 1 and 2.

The consensus statement offers clinicians seven key statements to help guide diagnosis and treatment of IgG4-related disease (see Table 1). The primary evidence available and used to base these statements on came primarily from individual small cohorts, case series and expert opinions in the literature, according to Dr. Khosroshahi. Each statement is accompanied by the percentage of experts who agreed with the statement, along with the quality of evidence based on the Oxford Centre for Evidence-Based Medicine (OCEBM), in which the level of evidence is graded from 1a-5 (1a being the best quality of evidence) and grade of recommendation ranges from A (strongest recommendation) to D (lowest).2 (For more information on the OCEBM grading system.)

Pages: 1 2 3 | Single Page

Filed Under: Conditions Tagged With: Clinical, Diagnosis, IgG4 related disease, outcome, patient care, TreatmentIssue: September 2015

You Might Also Like:
  • International Consensus Statement on the Management & Treatment of IgG4-Related Disease
  • Resarch Into IgG4-Related Diseases Expands Knowledge Base, Leads to Effective Treatments
  • Draft Classification Criteria for IgG4-Related Disease Introduced
  • Gene Signatures in IgG4-Related Disease

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.